Regulus Therapeutics

Developing Micro-RNA Therapeutics for Glioblastoma Patients

ABC2 became the first non-profit to partner with Regulus in an effort to expand their research portfolio to include brain cancer.  They are now working with Samsung Medical Center to develop a microRNA therapeutic to target the “master control switches” in brain tumors.

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs.  Regulus will apply its expertise in microRNA therapeutics to discover chemically modified oligonucleotide anti-miRs for testing at the Samsung Medical Center in preclinical models that mimic human brain cancer.

Learn more about the Regulus Therapeutic/ABC2 partnership.

 

Share |

Join us in our fight for a cure!

Twitter